About CBM Biopharma
CBM Biopharma is a Healthcare company based in Dallas (United States) founded in 2018, and was acquired by AIkido Pharma in June 2019. Small molecule therapeutics for cancer treatment are developed. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
CBM Biopharma was founded in 2018 in Dallas, United States, and operates in the biopharmaceutical sector focused on oncology. Small molecule-based therapeutics are developed to address cancer challenges. The drug candidate KPC34 is designed by combining a DNA damaging agent with targeted therapy to counter resistance mechanisms, targeting acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). DHA-dFdC has also been developed for pancreatic cancer treatment.
- Headquarters Dallas, United States
- Stage Acquired
- SectorsHealthcare
- Website cbmbiopharmainc.com
- Acquired by AIkido Pharma (Jun 2019)
- Investors
- Acquired byAIkido Pharma
(Jun 2019)
Investors in CBM Biopharma
CBM Biopharma has secured backing from 1 investor. Prominent investors backing the company include AIkido Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drugs for treating pancreatic cancer and leukemia are developed. | 1967 | aikidopharma.com | New York, United States |
Investor details for CBM Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CBM Biopharma
2 dated milestones of CBM Biopharma across 1 years, from founding to its latest funding, stage changes and deals.
- Founded CBM Biopharma is founded.
- Exit Acquired by AIkido Pharma.
Competitors of CBM Biopharma
CBM Biopharma has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of CBM Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as CBM Biopharma (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cbm Biopharma
Complete news archive for CBM Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CBM Biopharma
CBM Biopharma was founded in 2018.
CBM Biopharma is headquartered in Dallas, United States. It is registered at Dallas, Texas, United States.
CBM Biopharma was founded in 2018 in Dallas, United States, and operates in the biopharmaceutical sector focused on oncology. Small molecule-based therapeutics are developed to address cancer challenges. The drug candidate KPC34 is designed by combining a DNA damaging agent with targeted therapy to counter resistance mechanisms, targeting acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). DHA-dFdC has also been developed for pancreatic cancer treatment.
CBM Biopharma's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
CBM Biopharma has 1 investor. Key investors include AIkido Pharma.
Yes. CBM Biopharma was acquired by AIkido Pharma in June 2019.

